Bankruptcy Court Approves $7.4 Billion Purdue Settlement, Connecticut to Receive Up to $64 Million

The battle against Purdue Pharma and the Sackler family has stretched across courtroom calendars, state houses, funerals, and the shattered lives of millions of families. This week, it reached a pivotal moment. The United States Bankruptcy Court for the Southern District of New York confirmed a $7.4 billion settlement brought forward by 55 attorneys general, including Connecticut’s William Tong. The ruling marks one of the largest financial reckonings tied to the opioid crisis and permanently removes the Sackler family from the opioid industry in the United States. For Connecticut, the settlement means as much as $64 million in direct support over the next eight years—money that will fund addiction treatment, prevention efforts, and assistance to victims and their families. But for Attorney General Tong, the decision is more than a financial win. It is a symbolic banishment of a family whose name has become synonymous with devastation.

For nearly three decades, Purdue Pharma aggressively marketed opioid products such as OxyContin while the Sacklers shifted billions from the company into family accounts, insulating their wealth from accountability. They fueled the largest drug crisis in modern American history. As the overdose deaths mounted, families buried children, spouses, and parents, while the Sacklers published philanthropic donations and insisted that addiction was the byproduct of irresponsible patients and bad doctors. Today’s confirmation shatters that narrative. The agreement forces them to exit the industry they helped poison, closing the chapter on their ability to profit from pain.

The settlement will deliver resources faster than previous agreements. The Sacklers will pay $1.5 billion and Purdue will contribute roughly $900 million immediately, followed by scheduled payments of $500 million after one year, another $500 million after two years, and $400 million after three. Communities across the country will begin receiving funds within the first three years to support treatment infrastructure, overdose prevention, recovery programs, and direct payments to people who have lost loved ones. Tong has pushed for a significant portion of the early funding to be placed in a trust for survivors and the families of victims, an idea first included in the earlier $6 billion settlement that was derailed by the Supreme Court. If successful, the trust would represent one of the rare instances where money goes directly to the people most deeply wounded, rather than only to the systems responding to the aftermath.

The settlement also forces transparency. More than 30 million documents related to Purdue’s opioid business will become public, including compliance materials, marketing records, and documents once shielded by privilege. For six years, these records will be expanded to include information tied to the 2007 State Attorneys General settlement that Purdue violated almost immediately. Until now, the true internal playbook of one of the most profitable drug companies in history has remained largely sealed. Soon it will be a matter of record—emails, board presentations, distribution strategies, and the paper trail of the lies used to turn OxyContin into a national catastrophe.

This fight began in Connecticut in 2019 when Tong sued Purdue and individual Sackler family members, alleging they deceived doctors and patients to expand opioid sales while quietly extracting hundreds of millions from the company to protect personal fortunes. After Purdue filed bankruptcy later that year, the case shifted into the courts, where an initial plan would have granted the Sacklers sweeping lifetime legal immunity. That plan required $4.3 billion in payments over nine years and would have prevented states from pursuing their own claims. Connecticut, joined by eight other states and backed by the U.S. Trustee, appealed, arguing the bankruptcy court lacked the authority to release claims against non-debtor individuals. In December 2021, a federal district court agreed, overturning the arrangement and clearing the way for a stronger settlement. That revised $6 billion agreement was later struck down by the Supreme Court, triggering renewed mediation. The resulting $7.4 billion approval reflects not just a dollar increase, but a legal precedent reinforced through years of pushback, strategy, and refusal to accept immunity as a price of settlement.

This is not a victory in the conventional sense. No settlement will ever make whole the families who lost children at fifteen or forty-five. No restitution can return the decades stolen by addiction or undo the lives quietly destroyed. Tong acknowledged as much when he said the Sacklers’ name would stand forever beside greed and shame. Yet the settlement matters because it breaks the long American habit of treating corporate catastrophes as unavoidable accidents. It refuses to see opioid addiction as isolated personal failings and recognizes the industrial system that engineered demand, disguised risk, and monetized human suffering at scale.

Connecticut has already helped secure more than $50 billion nationwide to confront the opioid epidemic, with more than $600 million allocated to the state alone. Those funds are now flowing. The state’s Opioid Settlement Advisory Committee—made up of health professionals, people with lived experience, municipal leaders, and recovery advocates—will determine how they are deployed. That work is the real test: whether this settlement becomes another government windfall or a genuine path for families who have lived through loss.

The Sacklers have been forced out of the opioid business. Purdue Pharma will never again operate under their direction. The record of their actions will become public. And for the first time, states have affirmed that mass harm of this magnitude does not end with a check and a press release. It ends with accountability.

IF YOU NEED A LAWYER CONTACT US